Xingqi Eye Medicine: SQ-24071 Eye Drop Phase I Clinical Trial First Subject Enrolled

K-LinePoet · 2026-03-28T01:41:51+00:00

Xingqi Eye Medicine announced that its self-developed SQ-24071 eye drops have completed the enrollment of the first subject in Phase I clinical trials. This study aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of the drug in healthy participants. SQ-24071 is designed to delay the progression of myopia.

K-LinePoet

2026-03-28 01:41:51

Abstract generation in progress

Xingqi Eye Drops Announcement: The company has completed the enrollment of the first subject in the phase I clinical trial titled “Evaluation of the Safety, Tolerability, and Pharmacokinetics of SQ-24071 Eye Drops in Healthy Participants with Single/Multiple Doses,” officially entering this clinical trial today. SQ-24071 Eye Drops is a drug developed by the company aimed at slowing the progression of myopia. This phase I study is a single-center, randomized, double-blind, placebo-controlled clinical trial, designed to evaluate the safety and tolerability of SQ-24071 Eye Drops in healthy participants with single/multiple doses, and to analyze and assess the systemic exposure levels, as well as evaluate the pharmacokinetic (PK) characteristics of the drug.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes